Abivax (AAVXF) Current Deferred Revenue (2021 - 2023)

Abivax has reported Current Deferred Revenue for 3 years, with the latest figure at $55948.9 in Q4 2023.

• On a quarterly basis, Current Deferred Revenue fell 58.77% year-over-year to $55948.9 in Q4 2023; TTM through Dec 2023 was $55948.9, a 58.77% decrease from a year earlier, with the FY2023 full-year figure at $55948.9, down 58.77% from the prior year.
• Current Deferred Revenue was $55948.9 for Q4 2023 at Abivax, down from $135692.9 in the prior quarter.
• The five-year high for Current Deferred Revenue was $185323.3 in Q4 2021, with the low at $55948.9 in Q4 2023.
• Average Current Deferred Revenue over 3 years is $125655.0, with a median of $135692.9 recorded in 2022.
• The sharpest annual moves came in 2022 and 2023: Current Deferred Revenue slipped 26.78% in 2022, then slumped 58.77% in 2023.
• Over 3 years, Current Deferred Revenue stood at $185323.3 in 2021, then retreated by 26.78% to $135692.9 in 2022, then plunged by 58.77% to $55948.9 in 2023.
• The last three Current Deferred Revenue figures came in at $55948.9 (Q4 2023), $135692.9 (Q4 2022), and $185323.3 (Q4 2021), per Business Quant data.